Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 14/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448644 | 0.93 | CXCR3 (0.50) | CXCR3PDE10AMEN1KMT2AHSP90AA1 | |
| SCHEMBL452085 | 0.91 | CXCR3 (0.44) | CXCR3MEN1KMT2AUSP2TLR9 | |
| SCHEMBL451421 | 0.91 | CXCR3 (0.50) | CXCR3MEN1KMT2AHSP90AA1MAPT | |
| SCHEMBL453684 | 0.90 | CXCR3 (0.59) | CXCR3 | |
| SCHEMBL450680 | 0.90 | CXCR3 (0.49) | CXCR3PDE10AMEN1KMT2AHSP90AA1 | |
| SCHEMBL450887 | 0.90 | PRSS1 (0.46) | CXCR3MEN1KMT2AUSP2TLR9 | |
| SCHEMBL454538 | 0.89 | CXCR3 (0.47) | CXCR3PDE10AMEN1KMT2AHSP90AA1 | |
| SCHEMBL451971 | 0.89 | CXCR3 (0.47) | CXCR3PDE10AMEN1KMT2AHSP90AA1 | |
| SCHEMBL452977 | 0.88 | CXCR3 (0.53) | CXCR3 | |
| SCHEMBL448941 | 0.86 | CXCR3 (0.50) | CXCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | claimed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | CXCR3 741/4885PDE10A 1893/4885MEN1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.